APA (7th ed.) Citation

Vera, P., Thureau, S., Le Tinier, F., Chaumet-Riffaud, P., Hapdey, S., Kolesnikov-Gauthier, H., . . . Benali, K. (2024). Adaptive radiotherapy (up to 74 Gy) or standard radiotherapy (66 Gy) for patients with stage III non-small-cell lung cancer, according to [18F]FDG-PET tumour residual uptake at 42 Gy (RTEP7–IFCT-1402): A multicentre, randomised, controlled phase 2 trial. Lancet Oncology, 25(9), 1176. https://doi.org/10.1016/S1470-2045(24)00320-6

Chicago Style (17th ed.) Citation

Vera, Pierre, et al. "Adaptive Radiotherapy (up to 74 Gy) or Standard Radiotherapy (66 Gy) for Patients with Stage III Non-small-cell Lung Cancer, According to [18F]FDG-PET Tumour Residual Uptake at 42 Gy (RTEP7–IFCT-1402): A Multicentre, Randomised, Controlled Phase 2 Trial." Lancet Oncology 25, no. 9 (2024): 1176. https://doi.org/10.1016/S1470-2045(24)00320-6.

MLA (9th ed.) Citation

Vera, Pierre, et al. "Adaptive Radiotherapy (up to 74 Gy) or Standard Radiotherapy (66 Gy) for Patients with Stage III Non-small-cell Lung Cancer, According to [18F]FDG-PET Tumour Residual Uptake at 42 Gy (RTEP7–IFCT-1402): A Multicentre, Randomised, Controlled Phase 2 Trial." Lancet Oncology, vol. 25, no. 9, 2024, p. 1176, https://doi.org/10.1016/S1470-2045(24)00320-6.